Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Toripalimab for EGFR-mutated NSCLC
NCT06269211Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2024
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Ruijin Hospital. Primary endpoint: Major Pathological Response. Started Apr 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06269211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06269211.